SAVA:NSD-Cassava Sciences Inc (USD)

COMMON STOCK | Biotechnology | NSD

Last Closing Price

USD 45.85

Change

-2.50 (-5.17)%

Market Cap

USD 2.19B

Volume

2.97M

Avg Analyst Target

USD 117.50 (+156.27%)

Avg User Target

USD
Average Analyst Rating

Verdict

Fundamental Analysis

Verdict


Cassava Sciences Inc (SAVA) Stock Analysis:
Based on the Cassava Sciences Inc stock forecasts from 3 analysts, the average analyst target price for Cassava Sciences Inc is USD 117.50 over the next 12 months. Cassava Sciences Inc’s average analyst rating is Strong Buy. Stock Target Advisor’s own stock analysis of Cassava Sciences Inc is Neutral, which is based on 3 positive signals and 3 negative signals. At the last closing, Cassava Sciences Inc’s stock price was USD 45.85. Cassava Sciences Inc’s stock price has changed by -10.11 % over the past week, -10.81 % over the past month and +493.14 % over the last year.

About

Cassava Sciences, Inc., a clinical stage biotechnology company, develops drugs for neurodegenerative diseases. Its lead therapeutic product candidate is simufilam, a small molecule drug, which is completed Phase 2b clinical trial; and investigational diagnostic product candidate ...Read More

Technical Indicators

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2021-12-03 )

Largest Industry Peers for Biotechnology

Symbol Name Price(Change) Market Cap Price / Earning Ratio EV/EBITDA
MRNA Moderna Inc

+5.23 (+1.73%)

USD149.41B 18.61 18.13
BNTX BioNTech SE

+10.57 (+3.17%)

USD87.92B 10.55 8.07
REGN Regeneron Pharmaceuticals Inc

+1.16 (+0.18%)

USD67.82B 10.14 7.73
VRTX Vertex Pharmaceuticals Incorpo..

-0.64 (-0.31%)

USD48.34B 24.52 14.41
ALXN Alexion Pharmaceuticals Inc

N/A

USD40.34B 59.23 42.56
BGNE BeiGene Ltd

-31.73 (-9.17%)

USD33.38B N/A N/A
SGEN Seagen Inc

-7.93 (-5.00%)

USD29.26B 55.02 44.86
GMAB Genmab A/S

-0.30 (-0.80%)

USD25.21B 56.53 6.26
ALNY Alnylam Pharmaceuticals Inc

-11.49 (-6.28%)

USD21.98B N/A N/A
IMMU Immunomedics, Inc

N/A

USD20.31B N/A N/A

ETFs Containing SAVA

Symbol Name Weight Mer Price(Change) Market Cap

Market Performance

  Market Performance vs.
Industry/Classification (Biotechnology)
Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 572.29% 99% A+ 99% A+
Dividend Return N/A N/A N/A N/A N/A
Total Return 572.29% 99% A+ 99% A+
Trailing 12 Months  
Capital Gain 493.14% 98% A+ 99% A+
Dividend Return N/A N/A N/A N/A N/A
Total Return 493.14% 98% A+ 99% A+
Trailing 5 Years  
Capital Gain N/A N/A N/A N/A N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return N/A N/A N/A N/A N/A
Average Annual (5 Year Horizon)  
Capital Gain 537.10% 97% A+ 98% A+
Dividend Return N/A N/A N/A N/A N/A
Total Return 537.10% 97% A+ 98% A+
Risk Return Profile  
Volatility (Standard Deviation) 855.06% 3% F 2% F
Risk Adjusted Return 62.81% 90% A- 79% C+
Market Capitalization 2.19B 87% B+ 77% C+
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 87%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Key Financial Ratios

  Ratio vs. Industry/Classification
(Biotechnology)
Ratio vs. Market
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
Market Value  
Price / Earning Ratio N/A N/A N/A N/A N/A
Price/Book Ratio 8.17 15% F 16% F
Price / Cash Flow Ratio -406.12 99% A+ 95% A
EV/EBITDA N/A N/A N/A N/A N/A
Management Effectiveness  
Return on Equity -14.29% 88% B+ 42% F
Return on Invested Capital -11.08% 80% B- 33% F
Return on Assets -8.78% 86% B 30% F
Debt to Equity Ratio N/A N/A N/A N/A N/A
Technical Ratios  
Short Ratio 1.16 82% B- 73% C
Short Percent 22.11% 2% F 6% F
Beta 0.51 81% B- 83% B
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 97%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Ratings

Target Price Action Rating Action Analyst Rating Price Date

Discussions

User / Independent Analyst Ratings

User Name Target Rating Target Horizon (Months) Target Price User Analysis Date Comment

Fundamental Analysis Breakdown

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
High market capitalization

This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.

Superior risk adjusted returns

This stock has performed well, on a risk adjusted basis, compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile.

Superior Earnings Growth

This stock has shown top quartile earnings growth in the previous 5 years compared to its sector.

What to not like:
High volatility

The total returns for this company are volatile and above median for its sector over the past 5 years. Make sure you have the risk tolerance for investing in such stock.

Overpriced compared to book value

The stock is trading high compared to its peers median on a price to book value basis.

Negative cashflow

The company had negative total cash flow in the most recent four quarters.